Wednesday, October 14, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

News Corporation Q2 Earnings Surpass Estimates, Revenues Rise Y/Y

View original at finance.yahoo.com
News Corporation Q2 Earnings Surpass Estimates, Revenues Rise Y/Y News Corporation NWSA reported second-quarter fiscal 2026 earnings of 40 cents per share on an adjusted basis, which surpassed the Zacks Consensus Estimate by 21.21% and increased 21% year over year…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Competition is bringing out the best in REA, which is savvily adopting AI applications that enhance the service for customers

    80% confidence

  • News Corporation carries a Zacks Rank #4 (Sell)

    80% confidence

  • Management expressed mounting optimism for the second half of the year following a sluggish first quarter

    80% confidence

  • The company's three core growth pillars — Dow Jones, Digital Real Estate, and Book Publishing — collectively accounted for 95% of profitability in the fiscal second quarter

    80% confidence

  • Management cited a challenging print advertising market

    80% confidence

  • Share repurchases in fiscal 2026 are expected to benefit from approximately $380 million repayment of Foxtel shareholder loans

    80% confidence

  • Airbnb, Rush Street Interactive and Playtika carry a Zacks Rank #2 (Buy)

    80% confidence

  • At the current stock price, the company expects the purchase rate to be higher in the second half, with total dollars repurchased meaningfully more than in the first half

    80% confidence

  • Management believes the stock remains materially undervalued relative to net asset value

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com